CHICAGO, Illinois, October 10, 2012 - The Pharmaceutical Benchmarking Forum is celebrating its 15th anniversary. The group of 13, which is run by its members, comprises most of the world’s largest biopharma companies. Its greatest strengths are its unparalleled, detailed set of Discovery and Development data and its probing analyses. It explores overall R&D performance and such critical business questions as R&D productivity, success rates, cycle times, pipeline changes and directions, and resources, with rigorous evaluation of what drives performance.
The group has seen changes in its members brought on in most cases by consolidations, boosting average annual company R&D spending. It has examined why overall Development success rates have declined to 3.3% from 6.1% when the group first publicly reporting these figures in 2008. And it has analyzed why it takes longer to reach the market, requiring over 13 years to pass through R&D.
There are also distinct changes in the mix of their pipelines, with most increasing the portion of their portfolios related to biologics, which have been a positive source in recent success rates for certain companies.
In addition to its flagship study on R&D performance, the PBF sponsors additional studies, from a detailed analysis of the cost to develop a drug (by type of drug), an in-depth look at biologics R&D trends, and a study of high performance that assessed why some companies consistently outperform others in certain areas.
Relying on its unparalleled repository of detailed target and project data, coupled with investment information unmatched for its consistency, breadth, depth and reliability, PBF provides a rich resource for its membership and industry. From the start it has been facilitated by KMR Group, an independent firm that specializes in R&D analytics and information management. KMR works with the Forum to establish rigorous processes and instructions for the definition and collection of data and to assess and present the data in a blinded and meaningful way.
According to KMR Group’s Linda Martin, “The value the Forum provides to the Industry is difficult to overstate since there is no other organization that compares; it is built on 15 years of careful analysis and contributions by its members and relies on its unrivalled dataset, offering a crucial source for major biopharma to understand the R&D landscape and their place in it, as well as explore the factors that drive performance”.
The current members of the Forum are: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck Research Labs, Novartis, Novo Nordisk, Pfizer, Roche, and Sanofi.
For further information contact:
Linda Martin, Principal Tel: +1 (312) 795-0400 Email: firstname.lastname@example.org
KMR has been working exclusively in the biopharmaceutical R&D industry since the early 1990s. KMR is a leader in benchmarking, analytics and performance management as well as a developer of proprietary analytics software. With an exclusive focus on biopharmaceutical R&D and unrivaled commitment to data quality, KMR provides industry with the experience and knowledge to produce clear and uncompromising results in the form of reports, tools and presentations. We use our extensive, unparalleled datasets and experience within the industry to add value to the most pressing business questions. Please visit our website at https://kmrgroup.com